BioVie (Nasdaq:BIVI) - Stock Price, News & Analysis

BIVI Stock Overview

A clinical-stage biopharmaceutical company, develops drug therapies to treat neurological and neurodegenerative disorders, and advanced liver disease. More details

BIVI fundamental analysis
Snowflake Score
Valuation	0/6
Future Growth	0/6
Past Performance	0/6
Financial Health	6/6
Dividends	0/6

Rewards

Earnings have grown 4.8% per year over the past 5 years

Risk Analysis

Makes less than USD$1m in revenue ($0)

Shareholders have been substantially diluted in the past year

Highly volatile share price over the past 3 months compared to the US market

Does not have a meaningful market cap ($54M)

BioVie Inc. Competitors

SAB Biotherapeutics

NasdaqCM:SABS

US$28.9m

ImmuCell

NasdaqCM:ICCC

US$28.9m

HOOKIPA Pharma

NasdaqCM:HOOK

US$25.9m

RenovoRx

NasdaqCM:RNXT

US$30.9m

Price History & Performance

Summary of all time highs, changes and price drops for BioVie
Historical stock prices
Current Share Price	US$3.05
52 Week High	US$56.20
52 Week Low	US$1.04
Beta	0.90
11 Month Change	6.64%
3 Month Change	4.81%
1 Year Change	-94.18%
33 Year Change	-95.38%
5 Year Change	-94.45%
Change since IPO	-99.19%

Recent updates

BioVie: Recent Data In Alzheimer's Suggests +100% Upside Potential Within A Year

Oct 14

BioVie: Possibly Setting Up For Success With Alzheimer's And Parkinson's Results Imminent

Sep 06

BioVie: Four Potential Catalysts Around The Corner

Jun 07

Shareholder Returns

	BIVI	US Biotechs	US Market
7D	-10.6%	2.5%	2.2%
1Y	-94.2%	16.1%	31.6%

Return vs Industry: BIVI underperformed the US Biotechs industry which returned 16.1% over the past year.

Return vs Market: BIVI underperformed the US Market which returned 31.6% over the past year.

Price Volatility

Is BIVI's price volatile compared to industry and market?
BIVI volatility
BIVI Average Weekly Movement	38.2%
Biotechs Industry Average Movement	9.8%
Market Average Movement	6.3%
10% most volatile stocks in US Market	15.7%
10% least volatile stocks in US Market	3.1%

Stable Share Price: BIVI's share price has been volatile over the past 3 months compared to the US market.

Volatility Over Time: BIVI's weekly volatility has increased from 26% to 38% over the past year.

About the Company

Founded	Employees	CEO	Website
2013	14	Cuong Viet Do	bioviepharma.com

BioVie Inc., a clinical-stage biopharmaceutical company, develops drug therapies to treat neurological and neurodegenerative disorders, and advanced liver disease. The company develops BIV201 for the treatment of ascites due to chronic liver cirrhosis. It also develops NE3107 that is in Phase III clinical trial for the treatment of patients with mild to moderate Alzheimer’s disease; and in Phase 2 clinical trial to treat Parkinson’s disease, as well as for the long COVID program.

BioVie Inc. Fundamentals Summary

How do BioVie's earnings and revenue compare to its market cap?
BIVI fundamental statistics
Market cap	US$54.11m
Earnings (TTM)	-US$26.77m
Revenue (TTM)	n/a

0.0x

P/S Ratio

-2.0x

P/E Ratio

Is BIVI overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
BIVI income statement (TTM)
Revenue	US$0
Cost of Revenue	US$0
Gross Profit	US$0
Other Expenses	US$26.77m
Earnings	-US$26.77m

Last Reported Earnings

Sep 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)	-1.51
Gross Margin	0.00%
Net Profit Margin	0.00%
Debt/Equity Ratio	23.6%

How did BIVI perform over the long term?

See historical performance and comparison

BIVI Stock Overview

Rewards

Risk Analysis

BioVie Inc. Competitors

NasdaqCM:SABS

US$28.9m

NasdaqCM:ICCC

US$28.9m

NasdaqCM:HOOK

US$25.9m

NasdaqCM:RNXT

US$30.9m

Price History & Performance

Recent News & Updates

Biovie Inc. to Present Design of Planned Phase 2 Study of Bezisterim for the Treatment of Long Covid At Theemystifying Long Covid International Conference

BioVie Inc.'s Upcoming Parkinson’s Disease Clinical Trial Is Fully Funded

BioVie Inc. has completed a Follow-on Equity Offering in the amount of $3.24318 million.

BioVie Inc. has filed a Follow-on Equity Offering in the amount of $3.24318 million.

BioVie Inc. has completed a Follow-on Equity Offering in the amount of $6.00075 million.

BioVie Inc. has completed a Follow-on Equity Offering in the amount of $6.6645 million.

Recent updates

Biovie Inc. to Present Design of Planned Phase 2 Study of Bezisterim for the Treatment of Long Covid At Theemystifying Long Covid International Conference

BioVie Inc.'s Upcoming Parkinson’s Disease Clinical Trial Is Fully Funded

BioVie Inc. has completed a Follow-on Equity Offering in the amount of $3.24318 million.

BioVie Inc. has filed a Follow-on Equity Offering in the amount of $3.24318 million.

BioVie Inc. has completed a Follow-on Equity Offering in the amount of $6.00075 million.

BioVie Inc. has completed a Follow-on Equity Offering in the amount of $6.6645 million.

BioVie Inc. has filed a Follow-on Equity Offering in the amount of $6.6645 million.

BioVie Inc. Receives Notice of Allowance for Japan Patent Application Covering Novel Liquid Formulation of Terlipressin

BioVie Inc. Receives Notice of Allowance for United States Patent Application Covering Novel Liquid Formulation of Terlipressin

BioVie Inc. has completed a Follow-on Equity Offering in the amount of $2.995764 million.

New major risk - Market cap size

BioVie Inc. has filed a Follow-on Equity Offering.

BioVie Inc., Annual General Meeting, Nov 07, 2024

BioVie Inc. Secures All Scientific Approvals Needed to Receive Additional $12.6 Million of Grant Funding to Launch Planned Phase 2 Trial to Evaluate Bezisterim in Long Covid

Biovie Inc. Announces Fda Authorization of Investigational New Drug Application for Phase 2 Trial to Evaluate Bezisterim in Long Covid

Biovie Inc. Announces Clinical Data Showing Epigenetic Basis for How Bezisterim May Modulate Inflammation and the Biological Aging Process At the 11Th Aging Research and Drug Discovery Meeting

BioVie Inc. Announces Alignment with FDA on Clinical Trial to Assess Bezisterim in Parkinson’S Disease

New minor risk - Share price stability

BioVie Inc. Presents Protocol Design of Upcoming SUNRISE-PD Phase 2 Trial of Bezisterim in Patients with Early Parkinson's Disease at ATMRD 2024

BioVie Inc. Announces Its Bezisterim Demonstrates Potential Improvements in Sleep/Fatigue and Restless Leg Symptoms for Parkinson’s Disease Patients

New major risk - Financial position

BioVie Awards up to $13.1 Million in Funding from U.S. Department of Defense to Evaluate Bezisterim (NE3107) for the Treatment of Long COVID

BioVie Receives Notice of Delisting from Nasdaq Regarding Non-Compliance with the Minimum Bid Price Requirement Under Nasdaq Listing Rule 5550(a)(2)

BioVie Receives Notice of Delisting from Nasdaq Regarding Non-Compliance with the Minimum Bid Price Requirement Under Nasdaq Listing Rule 5550(a)(2)

BioVie Inc. Announces Pipeline Update and Near-Term Clinical Priorities

BioVie Inc. has completed a Follow-on Equity Offering in the amount of $21 million.

New major risk - Shareholder dilution

Block & Leviton LLP Files A Class Action Lawsuit Against BioVie Inc. and Certain of Its Executives, for Securities Fraud

Block & Leviton LLP Files A Class Action Lawsuit Against BioVie Inc. and Certain of Its Executives, for Securities Fraud

Independent Director recently sold US$128k worth of stock

New minor risk - Market cap size

BioVie Inc. Announces Efficacy Data from Phase 3 Trial of NE3107 in Patients with Mild to Moderate Alzheimer’s Disease

BioVie Inc. Presents Positive Clinical Safety Data from Phase 2b Trial of BIV201 in Refractory Ascites at the American Association for the Study of Liver Disease (AASLD) - The Liver Meeting® 2023

New major risk - Share price stability

BioVie Announces Late-Breaking Abstract Presenting Clinical Safety Data from the Company's Ascites Phase 2 Trial Accepted for Presentation at AASLD - The Liver Meeting®? 2023

BioVie Inc., Annual General Meeting, Nov 08, 2023

Price target increased by 11% to US$11.50

Insufficient new directors

BioVie Inc. Presents Data for NE3107 At 2023 International Congress of Parkinson’s Disease and Movement Disorders

Biovie Inc. Announces Phase 3 Trial of Ne3107 in Alzheimer's Disease

BioVie Inc. to Present Data Showing How NE3107 Potentially Regulates DNA Methylation of Specific Genes in a Manner Highly Correlated to Observed Improvements in Cognition and Biomarkers of Disease

Biovie Inc. Announces Additional Findings from Phase 2 Alzheimer’s Disease Trial: Ne3107 Appears to Impact Biomarkers of Aging-Related Disease States in Addition to Observed Reversal of Cognitive Decline in Dementia

BioVie Inc. Announces Positive Results for NE3107 in Parkinson’s and Alzheimer’s Phase 2 Trials

Biovie Inc. Phase 3 Trial Assessing Ne3107 in Alzheimer's Disease Has Fully Enrolled the Targeted 316 Patients

BioVie Inc. Phase 2 Trial Assessing Ne3107's Pro-Motoric Activity in Parkinson's Disease Is Fully Enrolled

BioVie: Recent Data In Alzheimer's Suggests +100% Upside Potential Within A Year

BioVie Inc., Annual General Meeting, Nov 09, 2022

BioVie Inc. Announces Topline Results from an Investigator-Sponsored Phase 2 Clinical Trial of NE3107 for the Treatment of Alzheimer’s Disease

BioVie: Possibly Setting Up For Success With Alzheimer's And Parkinson's Results Imminent

BioVie Inc. announced that it has received $6.000001 million in funding from Acuitas Group Holdings Llc

BioVie Inc. announced that it expects to receive $6.000001 million in funding from Acuitas Group Holdings Llc

BioVie Inc. announced that it expects to receive $6.000001 million in funding from Acuitas Group Holdings Llc

BioVie Announces Patent Issuance Covering Ascites Treatment with BIV201

BioVie: Four Potential Catalysts Around The Corner

BioVie Announces Treatment of First Patient in Phase 2 Clinical Trial of NE3107 for the Treatment of Parkinson’s Disease

BioVie Inc. Contemplates Bankruptcy

BioVie Inc. has completed a Follow-on Equity Offering in the amount of $20 million.

Biovie Announces First Patient Enrolled in Phase 3 Study of Ne3107 in Alzheimer’s Disease

BioVie Inc. Announces First Patient Enrolled in BIV201 Phase 2b Clinical Trial for Ascites